EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 673 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September August 27, 2025 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Navigating Life During and After Cancer As a Young Adult: A... November 29, 2022 Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Load more HOT NEWS Girl Scout’s Pink Chair Project Loans Recliners to Women Recovering from... A College Senior vs. A Global Pandemic Coping With Cancer Recurrence: My Perspective As Both a Patient and... Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research...
